After a number of pacts and buyouts over the past few years, Charles River Labs is cutting staff at one of its California sites.
According to a recent WARN notice, the CRO is cutting 24 employees from its San Diego site.
Charles River confirmed the cuts to FierceCRO today: “As part of our continuing efforts to streamline operations and enhance efficiencies, we have made the decision to close our research model production facility in San Diego and relocate all services and production to our Hollister site. Charles River is committed to maintaining its world-class client service and will ensure that the site closure will not impact availability or service.
“As part of this difficult but necessary decision, we are working with employees to ensure appropriate support and resources are in place as they seek new employment opportunities, both within and outside the company.”
Despite these cuts, over the past few months CRL has been spending, snapping up companies and making deals, including just two months back buying up early-stage CRO Citoxlab. A month before, it also went all-in for British CRO KWS BioTest in a £15 million ($20 million) deal. It’s also penned a new pact with Crown Bioscience for expanded access to the Zucker Diabetic Sprague-Dawley rat model.
By Ben Adams
Source: Fierce Biotech
The deal, announced Wednesday, has Sanofi paying $9.50 per share in cash for Kadmon, a roughly 77% premium to the biotech’s Tuesday closing price and 113% more than its average trading price over the last two months.
RSV, or respiratory syncytial virus, has long been a top target for vaccine developers. While companies have suffered high-profile trial failures over the years, vaccines are now advancing through late-stage testing and could launch in 2023, SVB Leerink analyst Geoffrey Porges wrote to clients this week.
By monitoring which areas of the brain responded to localized electrical stimulation, scientists from the Google Research Brain Team and Mayo Clinic developed an artificial intelligence algorithm to map out the structure of brain networks.